
Afzanna 40mg Tablet
Marketer
Celon Laboratories Ltd
Salt Composition
Afatinib dimaleate (40mg)
Overview Afzanna 40mg Tablet
Erlotinib 40mg tablets are indicated for treating non-small cell lung cancer in adults with specific epidermal growth factor receptor (EGFR) gene mutations. Optimal absorption requires administration on an empty stomach, consistently at the same time daily. Dosage and frequency are determined by your physician, based on your individual needs and may adjust over time; adhere strictly to their prescribed regimen. Incorrect usage or overdose can lead to severe adverse effects. Therapeutic benefits may not be immediately apparent; continue treatment unless instructed otherwise by your doctor. Common side effects include nausea, rash, dry skin, and diarrhea (which can be severe; manage it with prescribed medication and adequate hydration). Regular blood tests may be required. Photosensitivity is possible; use sunscreen and protective clothing when exposed to sunlight. Report eye pain, redness, or dryness to your physician. Prior to commencing treatment, disclose any respiratory, hepatic, or renal issues, or concurrent use of antimicrobial medications. Inform your healthcare provider of all medications being taken, as drug interactions are possible. This medication is contraindicated during pregnancy and lactation; reliable contraception is essential for female patients undergoing treatment.
Uses of Afzanna 40mg Tablet
Lung cancer (excluding small cell type)
Major Benefits of Afzanna 40mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Afzanna 40mg Tablet should be taken on an empty stomach.
Common Side effects of Afzanna 40mg Tablet:
- Diarrhea
- Rash
- Dry skin
- Nausea
- Vomiting
- Loss of appetite
- Itching
- Stomatitis (Inflammation of the mouth)
- Nail disorder
How to use Afzanna 40mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Afzanna 40mg Tablet should be taken on an empty stomach.
How Afzanna 40mg Tablet works:
Afzanna 40mg tablets are an anti-cancer drug that functions by targeting and blocking specific enzyme receptors (EGFR, HER2, and HER4) crucial for cancer cell proliferation. This action suppresses associated signaling pathways, thereby hindering or slowing cancer progression.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Afzanna 40mg Tablet and alcohol consumption.
PregnancyCONSULT YOUR DOCTOR
Using Afzanna 40mg tablets during pregnancy poses a confirmed risk to the fetus. Therefore, it's unsafe. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential advantages outweigh the known hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The use of Afzanna 40mg tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Afzanna 40mg Tablet on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Afzanna 40mg tablets appear to pose minimal risk for individuals with kidney impairment. Current evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Afzanna 40mg tablets appear to pose minimal risk for individuals with hepatic impairment. Current evidence indicates dose modification may not be necessary, but a physician's consultation is advised.
What if you forget to take Afzanna 40mg Tablet :
Omit any missed Afzanna 40mg Tablet dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Afzanna 40mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Quinazoline-Butenamide Hybrid |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Actions | Kinase inhibitors targeting tyrosine |
